The ATM increase, combined with the massive Armistice Capital resale registration and the company's going concern status, signals that bioAffinity will likely continue to rely on equity sales for funding. Monitor the pace of ATM sales and any further dilutive filings; the stock is under persistent selling pressure from both the ATM and the Armistice warrant shares.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 2 $3.19entry
- T+1 · yesterday −8.15%α −9.80% · $2.93
- T+2 · todayOpen
- T+5 · in 4d Pending
- T+20 · in 26d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
bioAffinity Technologies filed a 424B5 prospectus supplement to increase the aggregate amount of common stock it may sell under its existing at-the-market (ATM) sales agreement with WallachBeth Capital by up to $3,428,226, bringing the total ATM capacity to $5,228,226. The company has already sold 114,672 shares for approximately $1.3 million under the agreement. This ATM increase adds further potential dilution to a micro-cap stock with a $4 million market cap, a going concern opinion, and a history of persistent net losses.
Key Financial Metrics
Key Facts
- The company increased its ATM offering capacity by $3,428,226, for a total of up to $5,228,226 in common stock sales.
- 114,672 shares have already been sold under the ATM agreement for gross proceeds of approximately $1.3 million.
- The last reported sale price on October 30, 2026 was $2.91 per share, down from the $15.27 reference price used for the non-affiliate market value calculation.
- The company has a going concern opinion from its auditor and persistent net losses ($14.9 million in 2025).
- The market cap is approximately $4 million, making the potential ATM sales very large relative to the company's size.
- There have been 24 offering/registration filings in the last 24 months, indicating frequent capital raising.
- A prior S-3/A filed in September 2026 registered 1,692,408 shares for resale by Armistice Capital, representing ~282% dilution of then-outstanding shares.
Financial Impact
Up to $5,228,226 in potential additional common stock sales, which is approximately 131% of the current $4 million market cap.
Risk Factors
- Massive potential dilution from the ATM program (up to ~131% of current market cap) and the Armistice Capital warrant shares (~282% of prior outstanding).
- Going concern opinion and persistent net losses ($14.9 million in 2025) indicate the company may need to raise additional capital beyond this ATM.
- The stock price has fallen sharply from $15.27 (reference price used for non-affiliate calculation) to $2.91, suggesting significant selling pressure.
- High volatility (normal daily move of 17.9%) and low market cap ($4 million) make the stock susceptible to large price swings from any ATM sales.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001493152-26-049637 |
| Document: 0001493152-26-049637-index-headers.html | 0001493152-26-049637 |
| Document: 0001493152-26-049637-index.html | 0001493152-26-049637 |
| Document: 0001493152-26-049637.txt | 0001493152-26-049637 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 3, 2026 1d ago | 424B5 | $3.04 | awaiting T+60 | awaiting T+60 | $2.93 (+3.60%) |
Nov 2, 2026 2d ago | 424B5 | $3.19 | awaiting T+60 | awaiting T+60 | $2.93 (+8.15%) |
Oct 29, 2026 6d ago | 8-K | $3.03 | awaiting T+60 | awaiting T+60 | $2.93 (−3.30%) |
Oct 23, 2026 12d ago | DEF 14A | $2.83 | awaiting T+60 | awaiting T+60 | $2.93 (+3.53%) |
Oct 15, 2026 20d ago | 8-K | $3.96 | awaiting T+60 | awaiting T+60 | $2.93 (−26.01%) |
Oct 13, 2026 22d ago | 8-K | $3.63 | awaiting T+60 | awaiting T+60 | $2.93 (−19.17%) |
Oct 9, 2026 26d ago | 8-K | $3.90 | awaiting T+60 | awaiting T+60 | $2.93 (+24.87%) |
Oct 9, 2026 26d ago | 424B5 | $4.73 | awaiting T+60 | awaiting T+60 | $2.93 (+37.99%) |
Oct 9, 2026 26d ago | 424B5 | $4.73 | awaiting T+60 | awaiting T+60 | $2.93 (−37.99%) |
Oct 8, 2026 27d ago | 8-K | $5.64 | awaiting T+60 | awaiting T+60 | $2.93 (−48.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers